# Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

> **NCT00068952** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 118 (—)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Edotecarin
- **DRUG:** Temozolomide
- **DRUG:** Carmustine (BCNU)
- **DRUG:** Lomustine (CCNU)

## Key facts

- **NCT ID:** NCT00068952
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 118 (—)
- **Last updated:** 2008-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00068952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00068952, "Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00068952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*